vs
Harmony Biosciences Holdings, Inc.（HRMY）与BRC Group Holdings, Inc.（RILY）财务数据对比。点击上方公司名可切换其他公司
Harmony Biosciences Holdings, Inc.的季度营收约是BRC Group Holdings, Inc.的1.3倍（$243.8M vs $188.3M），BRC Group Holdings, Inc.净利率更高（47.9% vs 9.2%，领先38.7%），Harmony Biosciences Holdings, Inc.同比增速更快（21.1% vs -21.9%），过去两年Harmony Biosciences Holdings, Inc.的营收复合增速更高（25.6% vs -15.4%）
哈莫尼生物科学控股公司是一家处于商业化阶段的生物制药企业，专注于罕见神经及中枢神经系统疾病创新疗法的研发与商业化，核心产品针对发作性睡病等睡眠相关中枢神经系统病症，主要市场为美国。
HRMY vs RILY — 直观对比
营收规模更大
HRMY
是对方的1.3倍
$188.3M
营收增速更快
HRMY
高出43.0%
-21.9%
净利率更高
RILY
高出38.7%
9.2%
两年增速更快
HRMY
近两年复合增速
-15.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $243.8M | $188.3M |
| 净利润 | $22.5M | $90.3M |
| 毛利率 | 71.9% | 79.5% |
| 营业利润率 | 15.8% | 32.3% |
| 净利率 | 9.2% | 47.9% |
| 营收同比 | 21.1% | -21.9% |
| 净利润同比 | -54.6% | 1710.8% |
| 每股收益（稀释后） | $0.38 | $2.78 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HRMYRILY
| Q4 25 | $243.8M | $188.3M | ||
| Q3 25 | $239.5M | $215.3M | ||
| Q2 25 | $200.5M | $188.2M | ||
| Q1 25 | $184.7M | $197.2M | ||
| Q4 24 | $201.3M | $241.0M | ||
| Q3 24 | $186.0M | $225.5M | ||
| Q2 24 | $172.8M | $256.0M | ||
| Q1 24 | $154.6M | $263.4M |
净利润HRMYRILY
| Q4 25 | $22.5M | $90.3M | ||
| Q3 25 | $50.9M | $91.1M | ||
| Q2 25 | $39.8M | $139.5M | ||
| Q1 25 | $45.6M | $-10.0M | ||
| Q4 24 | $49.5M | $-5.6M | ||
| Q3 24 | $46.1M | $-284.4M | ||
| Q2 24 | $11.6M | $-433.6M | ||
| Q1 24 | $38.3M | $-49.2M |
毛利率HRMYRILY
| Q4 25 | 71.9% | 79.5% | ||
| Q3 25 | 75.1% | 83.7% | ||
| Q2 25 | 81.0% | 81.3% | ||
| Q1 25 | 82.7% | 81.4% | ||
| Q4 24 | 73.0% | 79.8% | ||
| Q3 24 | 77.0% | 82.1% | ||
| Q2 24 | 81.4% | 84.5% | ||
| Q1 24 | 82.2% | 85.3% |
营业利润率HRMYRILY
| Q4 25 | 15.8% | 32.3% | ||
| Q3 25 | 27.3% | 30.4% | ||
| Q2 25 | 24.0% | 5.7% | ||
| Q1 25 | 30.4% | -31.2% | ||
| Q4 24 | 27.7% | -69.2% | ||
| Q3 24 | 33.2% | -36.4% | ||
| Q2 24 | 12.4% | -90.8% | ||
| Q1 24 | 33.7% | -6.1% |
净利率HRMYRILY
| Q4 25 | 9.2% | 47.9% | ||
| Q3 25 | 21.2% | 42.3% | ||
| Q2 25 | 19.8% | 74.1% | ||
| Q1 25 | 24.7% | -5.1% | ||
| Q4 24 | 24.6% | -2.3% | ||
| Q3 24 | 24.8% | -126.1% | ||
| Q2 24 | 6.7% | -169.4% | ||
| Q1 24 | 24.8% | -18.7% |
每股收益（稀释后）HRMYRILY
| Q4 25 | $0.38 | $2.78 | ||
| Q3 25 | $0.87 | $2.91 | ||
| Q2 25 | $0.68 | $4.50 | ||
| Q1 25 | $0.78 | $-0.39 | ||
| Q4 24 | $0.85 | $-0.01 | ||
| Q3 24 | $0.79 | $-9.39 | ||
| Q2 24 | $0.20 | $-14.35 | ||
| Q1 24 | $0.67 | $-1.71 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $775.3M | $226.6M |
| 总债务越低越好 | $163.7M | $1.4B |
| 股东权益账面价值 | $870.2M | $-171.5M |
| 总资产 | $1.3B | $1.7B |
| 负债/权益比越低杠杆越低 | 0.19× | — |
8季度趋势，按日历期对齐
现金及短期投资HRMYRILY
| Q4 25 | $775.3M | $226.6M | ||
| Q3 25 | $672.6M | $184.2M | ||
| Q2 25 | $565.3M | $267.4M | ||
| Q1 25 | $507.0M | $138.3M | ||
| Q4 24 | $467.2M | $146.9M | ||
| Q3 24 | $410.5M | $159.2M | ||
| Q2 24 | $346.9M | $236.9M | ||
| Q1 24 | $372.4M | $190.7M |
总债务HRMYRILY
| Q4 25 | $163.7M | $1.4B | ||
| Q3 25 | $168.5M | $1.3B | ||
| Q2 25 | $172.1M | $1.3B | ||
| Q1 25 | $175.7M | $1.4B | ||
| Q4 24 | $179.3M | $1.5B | ||
| Q3 24 | $182.8M | — | ||
| Q2 24 | $186.4M | — | ||
| Q1 24 | $190.0M | — |
股东权益HRMYRILY
| Q4 25 | $870.2M | $-171.5M | ||
| Q3 25 | $835.1M | $-260.5M | ||
| Q2 25 | $773.1M | $-351.7M | ||
| Q1 25 | $720.5M | $-496.8M | ||
| Q4 24 | $659.2M | $-488.2M | ||
| Q3 24 | $596.8M | $-497.6M | ||
| Q2 24 | $538.6M | $-218.3M | ||
| Q1 24 | $515.4M | $228.4M |
总资产HRMYRILY
| Q4 25 | $1.3B | $1.7B | ||
| Q3 25 | $1.2B | $1.7B | ||
| Q2 25 | $1.1B | $1.5B | ||
| Q1 25 | $1.1B | $1.5B | ||
| Q4 24 | $999.2M | $1.8B | ||
| Q3 24 | $928.1M | $2.2B | ||
| Q2 24 | $858.4M | $3.2B | ||
| Q1 24 | $847.0M | $5.0B |
负债/权益比HRMYRILY
| Q4 25 | 0.19× | — | ||
| Q3 25 | 0.20× | — | ||
| Q2 25 | 0.22× | — | ||
| Q1 25 | 0.24× | — | ||
| Q4 24 | 0.27× | — | ||
| Q3 24 | 0.31× | — | ||
| Q2 24 | 0.35× | — | ||
| Q1 24 | 0.37× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $126.2M | $26.2M |
| 自由现金流经营现金流 - 资本支出 | $126.0M | — |
| 自由现金流率自由现金流/营收 | 51.7% | — |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | 5.61× | 0.29× |
| 过去12个月自由现金流最近4个季度 | $347.9M | — |
8季度趋势，按日历期对齐
经营现金流HRMYRILY
| Q4 25 | $126.2M | $26.2M | ||
| Q3 25 | $108.7M | $-60.6M | ||
| Q2 25 | $79.3M | $-25.6M | ||
| Q1 25 | $34.0M | $184.0K | ||
| Q4 24 | $75.6M | $-2.7M | ||
| Q3 24 | $70.5M | $19.5M | ||
| Q2 24 | $42.6M | $111.5M | ||
| Q1 24 | $31.1M | $135.4M |
自由现金流HRMYRILY
| Q4 25 | $126.0M | — | ||
| Q3 25 | $108.7M | — | ||
| Q2 25 | $79.3M | — | ||
| Q1 25 | $33.9M | — | ||
| Q4 24 | $75.0M | — | ||
| Q3 24 | $70.5M | — | ||
| Q2 24 | $42.0M | — | ||
| Q1 24 | $31.1M | — |
自由现金流率HRMYRILY
| Q4 25 | 51.7% | — | ||
| Q3 25 | 45.4% | — | ||
| Q2 25 | 39.6% | — | ||
| Q1 25 | 18.3% | — | ||
| Q4 24 | 37.3% | — | ||
| Q3 24 | 37.9% | — | ||
| Q2 24 | 24.3% | — | ||
| Q1 24 | 20.1% | — |
资本支出强度HRMYRILY
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.1% | — | ||
| Q4 24 | 0.3% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.4% | — | ||
| Q1 24 | 0.0% | — |
现金转化率HRMYRILY
| Q4 25 | 5.61× | 0.29× | ||
| Q3 25 | 2.14× | -0.66× | ||
| Q2 25 | 1.99× | -0.18× | ||
| Q1 25 | 0.75× | — | ||
| Q4 24 | 1.53× | — | ||
| Q3 24 | 1.53× | — | ||
| Q2 24 | 3.68× | — | ||
| Q1 24 | 0.81× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HRMY
暂无分部数据
RILY
| Transferred At Point In Time | $101.4M | 54% |
| Wealth Management Segment | $30.7M | 16% |
| Corporate Finance Consulting And Investment Banking Fees | $27.1M | 14% |
| Services And Fees | $24.8M | 13% |
| Commissions Fees And Reimbursed Expenses | $4.8M | 3% |
